Results 31 to 40 of about 280,725 (312)

Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E-2 production [PDF]

, 2004
Levels of prostaglandin E-2 (PGE(2)), a potent inhibitor of fibroblast function, are decreased in the lungs of patients with pulmonary fibrosis, which has been shown to be because of limited expression of cyclooxygenase-2 (COX-2).
McAnulty, R J, Martyn L. Foster, Laurent, G J, Rebecca J. Hodges, R. Gisli Jenkins, Geoffrey J. Bellingan, Jenkins, R G, Bellingan, GJ, Hart, S L, Laurent, GJ, Jenkins, RG, Bottoms, SE, Copeman, DM, Bottoms, S E, Geoffrey J. Laurent, Nanthakumar, C B, Foster, ML, Wheeler-Jones, C P D, Stephen L. Hart, Hodges, RJ, Wheeler-Jones, CPD, Robin J. McAnulty, Bellingan, G J, McAnulty, RJ, Nanthakumar, CB, Inst Child Hlth, Foster, M L, Stephen E. Bottoms, Copeman, D M, Caroline P.D. Wheeler-Jones, Carmel B. Nanthakumar, Hart, SL, Merck Sharp & Dohme, Hodges, R J, UCL, Danielle M. Copeman   +35 more
core   +1 more source

Enhanced IL-1β Release Following NLRP3 and AIM2 Inflammasome Stimulation Is Linked to mtROS in Airway Macrophages in Pulmonary Fibrosis [PDF]

, 2021
Fibrotic Interstitial lung diseases (ILDs) are complex disorders of variable clinical behaviour. The majority of them cause significant morbidity, whilst Idiopathic Pulmonary Fibrosis (IPF) is recognised as the most relentless.
Mastrodimou, Semeli, Molyneaux, Philip L, Invernizzi, Rachele, Tzanakis, Nikolaos, Vasarmidi, Eirini, Maher, Toby M, Bibaki, Eleni, Tsitoura, Eliza, Antoniou, Katerina, Trachalaki, Athina   +9 more
core   +1 more source

Treatment of pulmonary exacerbations in cystic fibrosis [PDF]

, 2020
Purpose of review This review will discuss the challenges of defining a pulmonary exacerbations in cystic fibrosis and the key pathogens, which contribute.
Nadig, Tejaswi, Flume, Patrick, Ng, Christabella, Smyth, Alan R.   +3 more
core   +2 more sources

Use of ivacaftor in late diagnosed cystic fibrosis monozygotic twins heterozygous for F508del and R117H-7T – a case report

BMC Pulmonary Medicine, 2019
Background CFTR modulator therapy with ivacaftor is a treatment option for Cystic Fibrosis (CF) patients with at least one copy of a R117H-7T mutation in the CFTR gene.
Matthias Welsner, Svenja Straßburg, Christian Taube, Sivagurunathan Sutharsan   +3 more
doaj   +1 more source

MicroRNAs in fibrosis: opportunities and challenges [PDF]

, 2016
MicroRNAs (miRNAs) are small, non-coding RNAs that mediate mRNA cleavage, translational repression or mRNA destabilisation and are around 22-25 nucleotides in length via partial complementary binding to the 3' untranslated region in target transcripts ...
O'Reilly, Steven, Steven O’Reilly
core   +1 more source

Quality of life is associated with physical activity and fitness in cystic fibrosis [PDF]

, 2014
BACKGROUND: Health-related and disease-specific quality of life (HRQoL) has been increasingly valued as relevant clinical parameter in cystic fibrosis (CF) clinical care and clinical trials.
Helge Hebestreit, Schmid, K, Junge, Sibylle, Hebestreit, Helge Uwe, Hebestreit, H, Schindler, C, Schmid, Kerstin, Kriemler, Susi, Christian Schindler, Schenk, T, Hebestreit, Alexandra, Ballmann, Manfred, Hebestreit, A, Kerstin Schmid, Stephanie Kieser, Hans-Georg Posselt, Manfred Ballmann, Thomas Schenk, Roth, K, Schenk, Thomas, Junge, S, Posselt, H G, Posselt, Hans-Georg, Sibylle Junge, Alexandra Hebestreit, Kieser, Stephanie, Hebestreit, Helge, Ballmann, M, Susi Kriemler, Schindler, Christian, Roth, Kristina, Kristina Roth   +31 more
core   +1 more source

Promoter variants in tissue inhibitor of metalloproteinase-3 (TIMP-3) protect against susceptibility in pigeon breeders' disease. [PDF]

, 2004
BACKGROUND: Tissue inhibitors of metalloproteinases (TIMPs) play a major role in extracellular matrix turnover in the lung. However, in chronic lung disorders such as idiopathic pulmonary fibrosis (IPF) and pigeon breeders' disease (PBD), TIMPs may ...
Briggs, L, Montaño, MM, Pardo, A, Estrada, A, Laurent, GJ, Selman, M, Hill, MR, Pardo-Cemo, Annie   +7 more
core   +1 more source

Modelling forced vital capacity in idiopathic pulmonary fibrosis: optimising trial design. [PDF]

, 2019
INTRODUCTION: Forced vital capacity is the only registrational endpoint in idiopathic pulmonary fibrosis clinical trials. As most new treatments will be administered on top of standard of care, estimating treatment response will become more challenging ...
Meyvisch, Paul, Santermans, Eva, Wijsenbeek, Marlies, Ford, Paul, Wuyts, Wim A, Maher, Toby M, Kreuter, M, Meyvisch, P, Molyneaux, Philip L., Wijsenbeek - Lourens, Marlies, Verbruggen, Nadia, Molyneaux, Philip L, Brown, Kevin K, Lederer, DJ, Maher, Toby M., Brown, KK, Molyneaux, PL, Byrne, AJ, Wuyts, WA, Lederer, David J, Moor, Catharina C, Brown, Kevin K., Moor, Karen, Byrne, Adam J, Lederer, David J., Maher, TM, Byrne, Adam J., Sivananthan, A, Sivananthan, Arunon, Kreuter, Michael, Ford, P, Verbruggen, N, Santermans, E, Moor, Catharina C., Wuyts, Wim A.   +34 more
core   +1 more source

Cough suppression and HRQoL in adult people with cystic fibrosis: an unexplored correlation

Health and Quality of Life Outcomes, 2022
Background Cough suppression assessed by embarrassment about coughing has been shown in adolescents with cystic fibrosis (CF) and negatively affects health-related quality of life (HRQoL) and clinical indicators of disease severity in adolescent females.
Ute Niehammer, Mathis Steindor, Svenja Straßburg, Sivagurunathan Sutharsan, Christian Taube, Matthias Welsner, Raphael Hirtz, Florian Stehling   +7 more
doaj   +1 more source

Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis. [PDF]

, 2012
Lung function, acute pulmonary exacerbations (APE), and weight are the best clinical predictors of survival in cystic fibrosis (CF); however, underlying mechanisms are incompletely understood.
Rogers, S.L., Sturrock, A., Carveth, Holly, William Walsh, Christen Lane, Walsh, W., James Moore, Li, Yanping, Keogh, R.H., Cox, D.R., Jun Chen (4238), Li, Y., Holly Carveth (143299), Carveth Holly, Judy L. Jensen (143284), William Walsh (143288), Anne Sturrock (143317), Liou Theodore G., Robert Paine III (143322), Ruth H. Keogh (143278), Paine, Robert, Teresa Clark (143295), Hoidal, John R, Cox David R., Adler Frederick R., Moore James, Hoidal John R., Liou, T.G., Shaunessy L. Rogers (143305), Rogers Shaunessy L., David R. Cox (77429), John R. Hoidal (143328), Lane Christen, Lane, C., Ruth H Keogh, Chen, Jun, Packer Kristyn, Kristyn Packer (143291), Frederick R. Adler (143274), Packer, K., Paine Robert, Clark, Teresa, Keogh, Ruth H, Anne Sturrock, Paine, R., Theodore G Liou, David R Cox, Robert Paine, Walsh William, Packer, Kristyn, Hoidal, J.R., Jensen, Judy L, Sturrock, Anne, Yanping Li (90163), Moore, J., Sturrock Anne, Kristyn Packer, Shaunessy L Rogers, Frederick R Adler, Adler, F.R., Clark, T., Rogers, Shaunessy L, Jensen, J.L., Yanping Li, Keogh Ruth H., Chen Jun, Adler, Frederick R, Jun Chen, Liou, Theodore G, Clark Teresa, Theodore G. Liou (143270), Judy L Jensen, John R Hoidal, Li Yanping, Lane, Christen, Christen Lane (143311), Holly Carveth, Chen, J., James Moore (22922), Walsh, William, Teresa Clark, Carveth, H., Jensen Judy L., Cox, David R, Moore, James   +84 more
core   +1 more source